Dear Sir, Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please note that the Board in their meeting held ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Omkar Pharmachem Ltd, at its meeting held on August 13, 2025, approved the unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26). The company reported zero revenue from operations, with total income of Rs 13.50 lakh coming entirely from 'Other Operating Income' — flat compared to both Q4 FY25 (Rs 13.50 lakh) and Q1 FY25 (Rs 13.50 lakh). Total expenses rose to Rs 9.92 lakh from Rs 8.60 lakh a year ago, leading to a profit before tax of Rs 3.58 lakh (vs Rs 4.90 lakh in Q1 FY25). Profit after tax stood at Rs 2.66 lakh (vs Rs 4.90 lakh in Q1 FY25), translating to an EPS of Rs 0.03. The limited review report by Dipal R. Shah & Co. was unqualified. Notably, the company's other equity stands at negative Rs 65.00 lakh, indicating accumulated losses, even as paid-up equity capital remains at Rs 1,008.37 lakh.
The company shows minimal operational activity with no core sales revenue, and PAT declined roughly 46% year-on-year. The negative other equity is a red flag for long-term financial health, though near-term results remain marginally profitable. Shareholders should watch for any revival in operating revenue and improvement in reserves.